Alvotech (ICE: ALVO)

Market Cap	497.62B
Revenue (ttm)	12.91B
Net Income (ttm)	-76.30B
Shares Out	266.82M
EPS (ttm)	-336.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,469
Open	1,875.00
Previous Close	1,870.00
Day's Range	1,860.00 - 1,875.00
52-Week Range	890.00 - 2,500.00
Beta	-0.02
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Iceland
• Stock Exchange: Nasdaq Iceland
• Ticker Symbol: ALVO

Financial Performance

In 2023, Alvotech's revenue was $93.38 million, an increase of 9.84% compared to the previous year's $85.02 million. Losses were -$551.73 million, 7.43% more than in 2022.

Financial numbers in USD